Association of genetic polymorphisms in \textit{SOD2}, \textit{SOD3}, \textit{GPX3}, and \textit{GSTT1} with hypertriglyceridemia and low HDL-C level in subjects with high risk of coronary artery disease

Nisa Decharatchakul\textsuperscript{1,2}, Chatri Settasatian\textsuperscript{2,3}, Nongnuch Settasatian\textsuperscript{2,4}, Nantarat Komanasin\textsuperscript{2,4}, Upa Kukongviriyapan\textsuperscript{2,5}, Phongsak Intharaphet\textsuperscript{2,6} and Vichai Senthong\textsuperscript{2,6,7}

\textsuperscript{1} Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand
\textsuperscript{2} Cardiovascular Research Group, Khon Kaen University, Khon Kaen, Thailand
\textsuperscript{3} Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
\textsuperscript{4} School of Medical Technology, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand
\textsuperscript{5} Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
\textsuperscript{6} Queen Sirikit Heart Center of the Northeast, Khon Kaen University, Khon Kaen, Thailand
\textsuperscript{7} Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

\textbf{ABSTRACT}

\textbf{Background.} Oxidative stress modulates insulin resistant-related atherogenic dyslipidemia: hypertriglyceridemia (HTG) and low high-density lipoprotein cholesterol (HDL-C) level. Gene polymorphisms in superoxide dismutase (\textit{SOD2} and \textit{SOD3}), glutathione peroxidase-3 (\textit{GPX3}), and glutathione \textit{S}-transferase theta-1 (\textit{GSTT1}) may enable oxidative stress-related lipid abnormalities and severity of coronary atherosclerosis. The present study investigated the associations of antioxidant-related gene polymorphisms with atherogenic dyslipidemia and atherosclerotic severity in subjects with high risk of coronary artery disease (CAD).

\textbf{Methods.} Study population comprises of 396 subjects with high risk of CAD. Gene polymorphisms: \textit{SOD2} rs4880, \textit{SOD3} rs2536512 and rs2855262, \textit{GPX3} rs3828599, and \textit{GSTT1} (deletion) were evaluated the associations with HTG, low HDL-C, high TG/HDL-C ratio, and severity of coronary atherosclerosis.

\textbf{Results.} \textit{SOD2} rs4880-CC, \textit{SOD3} rs2536512-AA, rs2855262-CC, and \textit{GPX3} rs3828599- AA, but not \textit{GSTT1}\textsuperscript{1/-} individually increased risk of HTG combined with low HDL-C level. With a combination of five risk-genotypes as a genetic risk score (GRS), GRS \geq 6 increased risks of low HDL-C, high TG/HDL-C ratio, and severity of coronary atherosclerosis.

\textbf{Conclusion.} Combined polymorphisms in antioxidant-related genes increased the risk of dyslipidemia related to atherosclerotic severity, suggesting the combined antioxidant-related gene polymorphisms as predictor of atherogenic dyslipidemia.
Atherosclerosis is the major cause of coronary artery disease (CAD). Atherogenesis is a complex interplay of abnormal plasma lipid level (dyslipidemia), oxidative stress, and dysfunctional endothelial cells. In addition, genetic variations have also been implicated as a potent risk-predictor for CAD. Primary low level of high-density lipoprotein cholesterol (HDL-C), isolated hypertriglyceridemia (HTG), high triglycerides (TG) to HDL-C ratio (TG/HDL-C), as well as a combination of high TG with low HDL-C levels have also emerged as risk factors for cardiovascular events, including CAD (Ahmed et al., 2016; Da Luz et al., 2008; Klempfner et al., 2016; Lee et al., 2017).

Oxidative stress is the stage of redox imbalance; where the oxidant activity, mostly from reactive oxygen species (ROS), overwhelms the defense capacity of the endogenous antioxidant system. Oxidative stress plays a role in endothelial dysfunction and atherosclerotic process (Kattoor et al., 2017). A number of in vitro and population studies have provided strong evidence that oxidative stress is the key mechanism in insulin resistance (IR) (Ding et al., 2016; Maslov et al., 2019; Meigs et al., 2007; Park et al., 2009). IR enables adipocyte lipolysis that increases hepatic in-flux of free fatty acids (FFA), by which it induces hepatic TG synthesis. This leads to increased hepatic secretion of TG-rich very low-density lipoprotein (VLDL) and results in elevated blood TG level (Welty, 2013). Moreover, and in vitro study has reported that high ROS levels down-regulated APOAI gene expression and ApoA-I secretion. Because ApoA-I is the major protein component in HDL biosynthesis, therefore oxidative stress-related suppression of ApoA-I also has an effect on lowering HDL-C level (Shavva et al., 2017).

The major antioxidant enzymes that maintain redox homeostasis include superoxide dismutase (SOD), glutathione peroxidase (GPX), and glutathione S-transferase (GST). SOD2 and SOD3, which localize respectively within mitochondrial matrix and to the cell surface, catalyze the dismutation of superoxide (O$_2^{•−}$) into hydrogen peroxide (H$_2$O$_2$) (Karlsson, Lindahl & Marklund, 1988; Karnati et al., 2013) whereas GPX3, an antioxidant component in HDL fraction, involved in detoxification of extracellular H$_2$O$_2$ and lipid hydroperoxides (Chen et al., 2000). Both O$_2^{•−}$ and H$_2$O$_2$ are potent ROS found in mitochondria, cytosol, and extracellular compartment. There are reports showing that accumulation of these ROS in mitochondria and influx of extracellular ROS contribute to cellular IR (Fazakerley et al., 2018; Iwakami et al., 2011) which may be suppressed by SOD and GPX through their neutralizing of these ROS. Furthermore, over-expression of Sod2 in the rat (Boden et al., 2012) and Sod3 in the mouse (Cui et al., 2014) have prevented high fat diet-induced IR. In addition, induced-expression of GPX3 in human skeletal muscle cells has also inhibited oxidative stress-induced IR (Chung et al., 2009), a condition...
associated with HTG and low HDL-C level. Glutathione S-transferase theta 1 (GSTT1), a member of cytosolic GSTs, plays a key role in termination of phospholipid oxidation by detoxifying phospholipid hydroperoxide (Hurst et al., 1998). In vitro studies have revealed that 4-hydroperoxy-nonenal (4-HNE), an end product of phospholipid oxidation (Reis & Spickett, 2012), can induce IR in adipocytes, and activation of GST protein expression can prevent 4-HNE-induced IR and lipolysis in adipocytes (Liu et al., 2018).

As genetic variations are the underlying risk factors for almost all complex diseases; we speculated that polymorphisms in these antioxidant genes may modify their gene function that affects their antioxidant activities associated with dyslipidemia and risk for CAD. The SOD2 c.47C>T polymorphism (Ala16Val, rs4880) has been associated with the risks of CAD (Souiden et al., 2016) and type 2 diabetes mellitus (T2DM) (Vats et al., 2015). The SOD3 c.172G>A polymorphism (Ala58Thr, rs2536512) has also been associated with a risk of T2DM (Yang, Xie & Jin, 2016) but not hypertension (HT) (Dong et al., 2014). Another SOD3 polymorphism, g.9892T>C (rs2855262), is localized in 3’ untranslated region (3’UTR) (Crocco et al., 2016) and, as a linkage single nucleotide polymorphism (SNP) in SOD3 haplotype, has been associated with decreased severity of acute-infected lung injury (Arcaroli et al., 2009). The GPX3 c.87+1494A>G polymorphism (rs3828599), localized in the first intron of this gene, has been associated with essential HT (Hao et al., 2011). Several reports have provided the evident association between GSTT1 deletion polymorphism (GSTT1 + or −) and risk of CAD; however, with variable results (Song et al., 2017). GSTT1 deletion carriers have higher blood levels of TG, VLDL-C, and TG/HDL-C ratio (Maciel et al., 2009; Pinheiro et al., 2013) and lower level of HDL-C (Maciel et al., 2009).

Because five polymorphisms from four genes—SOD2 rs4880, SOD3 rs2536512 and rs2855262, GPX3 rs3828599, and GSTT1 (deletion)—have previously been reported their association with oxidative stress-related CAD risk factors such as HT and T2DM (Hao et al., 2011; Petrovic & Peterlin, 2014; Vats et al., 2015; Yang, Xie & Jin, 2016), they may implicate in lipid abnormalities and severity of coronary atherosclerosis in individuals with CAD. These gene polymorphisms were therefore selected for the present study. However, most of the previous reports have provided evidence from single gene polymorphisms and demonstrated inconsistent results. For complex diseases, genetic associations provided by single polymorphisms are usually of small magnitude (odds ratios 1.1–1.5) and usually elucidate only 1–8% of the overall disease risk in the population; the combined or additive effect of multiple genetic variants from different loci may account for a greater proportion of the disease risk (Ioannidis, 2003). However, the associations of combined polymorphisms in these genes with lipid abnormalities and atherosclerotic severity have never been studied in subjects with high risk of coronary artery disease (CAD). We hypothesized that subjects who carry a combined risk genotype from five polymorphisms would have a greater risk of having lipid abnormalities and contribute to the severity of coronary atherosclerosis compared to those with combined non-risk genotypes. The present study, therefore, aimed to evaluate the associations of individual and combined SOD2, SOD3, GPX3, and GSTT1 gene polymorphisms with lipid abnormalities, particularly HTG and low HDL-C level.
in subjects with high risk of CAD, and to further investigate the associations of these polymorphisms and lipid abnormalities with the severity of coronary atherosclerosis.

**MATERIALS & METHODS**

**Study population**
The study population were recruited from Thai subjects who attended for CAD investigation at Queen Sirikit Heart Center of the Northeast, Faculty of Medicine, Khon Kaen University, Thailand, between 2008 and 2012. These subjects, indicated as “high-risk subjects”, had signs or symptoms suspecting of CAD (reviewed in Cassar et al., 2009) and/or history of cardiovascular risk factors such as smoking, dyslipidemia, diabetes mellitus, hypertension, or obesity. Participants who had unstable angina, left ventricular hypertrophy, heart failure, cardiomyopathy, arrhythmia, and undergoing percutaneous coronary intervention or stent implantation, as well as those who were diagnosed with renal diseases, liver diseases, cancers, and inflammatory diseases, were excluded from the study. After providing the detail of the study, 396 participants, aged between 30 and 86 years, had voluntarily joined the study and gave written consent forms as well as demographic and risk factor information. Physical examination and blood collection were conducted for these participants, before being referred to the Cardiac Catheterization Unit for coronary angiography. There were 389 subjects who underwent elective, non-urgent coronary angiography in the absence of emergency conditions. Based on coronary angiography, 225 patients who had at least one of the main coronary arteries showing ≥50% luminal stenosis were defined as CAD, whereas 164 subjects having none or with <50% luminal stenosis were categorized as non-CAD (Scanlon et al., 1999).

**Ethics statement**
The study protocols, as being performed in human participants, were examined and approved by the Khon Kaen University Ethics Committee for Human Research and were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The approval certificate for Ethics in Human Research for Experimental studies, HE510414, was obtained.

**Assessment for the severity of coronary atherosclerosis**
The severity of coronary atherosclerosis, based on angiographic data, was evaluated using “Gensini score (GS)”, which is correlated with “atherosclerotic plaque burden” (Neeland et al., 2012). GS was calculated as the sum of “individual lesion score”—based on the degree of luminal stenosis, the involved coronary vessel, and its location along the target vessel—according to a previously described method (Yongsakulchai et al., 2016). To evaluate the severity of coronary atherosclerosis, the subjects were categorized into two groups using the median GS, 32 points in this study population, as the cut-off point between two groups being assigned as “absent to mild” and “moderate to severe” coronary atherosclerosis.
Blood biochemical parameters and demographic data
Venous blood was collected after 12 h fasting; for high-risk group, blood was collected before undergoing coronary angiography. Blood lipid parameters and fasting blood sugar (FBS) were determined using Cobas Integra 400 chemistry autoanalyzer (Roche diagnostic, Switzerland). LDL-C was calculated using the Friedewald equation for samples with TG concentrations <4.5 mmol/L. Serum high-sensitivity C-reactive protein (hs-CRP) was measured using the BN ProSpec® System (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany). Fasting insulin level was determined by sandwich immunoassay (Cisbio Bioassays, Bedford, MA, USA). The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated by \[\text{HOMA-IR} = \frac{\text{FBS (mmol/L)} \times \text{fasting insulin level (µU/mL)}}{22.5}\] (Matthews et al., 1985).

Obesity was identified from body mass index (BMI) of ≥25 kg/m² (WHO, 2000). Diabetes mellitus (DM) was identified by prior physician diagnosis or FBS ≥7.0 mmol/L (American Diabetes Association, 2013). Hypertension (HT) was defined if: (i) subject received the antihypertensive drug, or (ii) from prior physician diagnosis, or (iii) whose blood pressure reading ≥140 mmHg for systolic blood pressure (SBP) or ≥90 mmHg for diastolic blood pressure (DBP) (Weber et al., 2014). All abnormal lipid and lipoprotein profiles were followed the National Cholesterol Education Program and Adult Treatment Panel III (NCEP-ATP III) guideline. Low HDL-C level was considered from a value of HDL-C below the 50th percentile (HDL-C <1.0 mmol/L). Hypertriglyceridemia (HTG) was defined by fasting serum for TG level of ≥1.7 mmol/L. Subject who had an abnormal level of one or more lipid profiles, or currently on the lipid-lowering drug, or had a history of lipid disorder was defined as “dyslipidemia (DL)”. The cut-off point for “high TG/HDL ratio (in mg/dL unit)” in the present study was 3.7, as determined by constructing the ROC curves for prediction of atherosclerotic severity. In addition, the TG/HDL-C ratio ≥3, as a surrogate marker of insulin resistance (IR) (Hannon et al., 2006; Iwani et al., 2017) was also included in the evaluation. Metabolic syndrome (MetS) was defined for subjects who had three or more of five conditions according to the International Diabetes Federation (IDF) and NCEP-ATP III criteria.

Genotyping of antioxidant gene polymorphisms
The polymorphisms of antioxidant genes were selected based on data from the previous reports showing evidence of association with CVD risk factors in various populations, except for SOD3 g.9892T>C (rs2855262). This SNP comprises two polymorphic, T and C alleles that generate three possible genotypes (TT, TC, and CC). Although there was no report of association between SOD3 rs2855262 and CVD risk factors, this SNP was selected based on prior pilot study showing its relationship with oxidative stress markers in subjects with MetS, aged >50 years; subjects with CC had a higher level of malondialdehyde (MDA) than those with TT \((p = 0.010)\) (Table S1).

Genomic DNA was extracted from peripheral blood leukocytes using the Flexi Gene DNA isolation kit (QIAGEN, Germany). GSTT1 deletion polymorphism was determined by multiplex polymerase chain reaction (multiplex PCR) previously described by
With some modification. SOD2, SOD3, and GPX3 SNPs were determined using allele-specific polymerase chain reaction (AS-PCR) technique. GeneFisher software (Giegerich, Meyer & Schleiermacher, 1996) was used in designing the PCR primers. Details of genotyping are provided in the Data S1.

For each gene polymorphism, the genotyping results were validated by DNA sequencing (1st BASE, Selangor, Malaysia) of at least 10% randomly selected samples. The DNA sequencing results confirmed all genotyping results of all gene polymorphisms in all randomly selected samples (examples of DNA sequencing profiles are shown in Data S2).

Genetic risk scores
To evaluate the combined effect, genetic risk score (GRS) was formulated based on risk-contributing alleles across multiple polymorphisms. For each bi-allelic locus, an individual may possibly have risk score 0, 1, or 2. A GRS was calculated by the summation of risk alleles from all five polymorphisms: SOD2 rs4880, SOD3 rs2536512, SOD3 rs2855262, GPX3 rs3828599, and GSTT1 (deletion). For five polymorphisms, an individual would theoretically have GRS between scores 0 and 10.

Statistical analysis
Statistical analysis was performed using the SPSS software version 17 (SPSS inc., Chicago, IL). The genotype frequency and categorical variable differences between case and control subjects were assessed by Chi-square analysis. The genotype distributions were tested for Hardy–Weinberg equilibrium (HWE) using HW calculator provided by Santiago Rodriguez (http://www.oege.org/software/hwe-mr-calc.shtml). The associations between genotypes and the risks of metabolic disorders were analyzed using a logistic regression model and expressed as Odds Ratio (OR) with 95% confidence interval (95% CI). For multiple testing, the results for the GRS-phenotype associations were corrected using a Bonferroni correction, based on the number of calculated GRSS (n = 5). This study set significance at a Bonferroni corrected alpha (α) [corrected p < 0.010, α = 0.050/5]. Continuous variables were first tested for normal distribution utilizing the Kolmogorov–Smirnov normality test. Those variables with skewed distribution were log_{10}-transformed before subsequent data analysis. Student’s t-test was used to compare the means of continuous variables between two groups. One way analysis of variance (ANOVA) was used to compare variables among three or more groups and followed by a post hoc test (Scheffe’s procedure). The polynomial linear trend test was used to assess linear trends across genotype or GRS groups for continuous variables. All continuous variables were expressed as means ± standard deviation (SD). Statistical significance was considered as a two-tailed p-value <0.05. Sample size and power calculations are shown in Table S2.

RESULTS
Baseline demographics and clinical characteristics of the study population
For further analysis, the study population was first divided into two groups based on the degree of coronary atherosclerosis, using Gensini score (GS) 32 as the cut-off point, and
Table 1  Baseline demographics and clinical characteristics of the study population.

| Parameter                         | Gensini score ≤32; N (%) (n = 268) | Gensini score >32; N (%) (n = 121) | p-value |
|-----------------------------------|-------------------------------------|-------------------------------------|---------|
| Gender: Male, n (%)               | 143 (53.4%)                         | 85 (70.2%)                          | 0.002   |
| Female, n (%)                     | 125 (46.6%)                         | 36 (29.8%)                          |         |
| Smoking status; n (%)             | 89 (33.2%)                          | 51 (42.1%)                          | 0.089   |
| High TG/HDL-C (≥3; unit mg/dL)    | 158 (59.0%)                         | 87 (71.9%)                          | 0.014   |
| High TG/HDL-C (≥3.7; unit mg/dL)  | 124 (46.3%)                         | 72 (59.5%)                          | 0.016   |
| Metabolic syndrome; n (%)         | 154 (60.4%)                         | 78 (67.8%)                          | 0.171   |
| CAD; n (%)                        | 105 (39.2%)                         | 120 (99.2%)                         | <0.001  |
| Age (year)                        | 60.2 ± 9.0                          | 63.1 ± 9.2                          | 0.004   |
| Gensini score                     | 7.1 ± 9.7                           | 67.7 ± 33.2                         | <0.001  |
| HOMA-IR                           | 5.29 ± 5.09                         | 7.47 ± 12.23                        | 0.102   |
| SBP (mmHg)                        | 129.5 ± 18.7                        | 129.4 ± 18.5                        | 0.972   |
| DBP (mmHg)                        | 74.1 ± 10.3                         | 72.5 ± 11.6                         | 0.118   |
| BMI (kg/m²)                       | 24.7 ± 3.7                          | 24.7 ± 3.0                          | 0.680   |
| Waist/hip ratio                   | 0.94 ± 0.07                         | 0.97 ± 0.07                         | 0.014   |
| FBS (mmol/L)                      | 6.21 ± 2.61                         | 6.44 ± 2.66                         | 0.395   |
| TC (mmol/L)                       | 4.43 ± 1.08                         | 4.75 ± 1.46                         | 0.033   |
| TG (mmol/L)                       | 1.86 ± 1.05                         | 2.18 ± 1.31                         | 0.013   |
| HDL-C (mmol/L)                    | 1.10 ± 0.34                         | 1.00 ± 0.26                         | 0.009   |
| LDL-C (mmol/L)                    | 2.48 ± 0.91                         | 2.77 ± 1.16                         | 0.017   |
| TG/HDL-C (unit: mmol/L)           | 1.95 ± 1.54                         | 2.46 ± 1.86                         | 0.003   |
| TG/HDL-C (unit: mg/dL)            | 4.46 ± 3.53                         | 5.62 ± 4.25                         | 0.003   |
| hsCRP (mg/L)                      | 4.10 ± 10.16                        | 4.11 ± 7.01                         | 0.492   |

Notes.
Abbreviations: HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein.
Categorical variables are presented as percentage of subject in each group and continuous variables are presented as mean ± SD.

was assigned as “absent to mild” (GS ≤ 32) and “moderate to severe” (GS > 32) coronary atherosclerosis. The baseline demographics and clinical characteristics of study subjects based on GS are demonstrated in Table 1. The number of male subjects in “moderate to severe” coronary atherosclerosis group (70.2%) was higher than in “absent to mild” coronary atherosclerosis group (53.4%), p = 0.002. The frequencies of subjects with high TG/HDL-C ratio were significantly higher in “moderate to severe” than in “absent to mild” groups. As compared with “absent to mild”, patients with “moderate to severe” atherosclerosis had significantly higher average age, Gensini score (GS), and waist/hip ratio; higher levels of TC, TG, LDL-C, and TG/HDL-C; and lower level of HDL-C.
Associations of SOD2, SOD3, GPX3, and GSTT1 polymorphisms with TG and HDL-C dyslipidemia

The distribution of genotypes and alleles for all gene polymorphisms in the study population followed HWE (p > 0.05). The frequencies of minor alleles: SOD2 rs4880-C, SOD3 rs2536512-A, SOD3 rs2855262-C, GPX3 rs3828599-A, and GSTT1 (+) were 25.0%, 39.1%, 42.7%, 43.3%, and 42.7%, respectively. Linkage disequilibrium (D′ = 0.82) between two SOD3 polymorphisms was also observed in this population. The step-wise relationship between genotypes and TG and HDL-C levels in each individual polymorphism is summarized in Table 2 (showing p for trend).

Assessment by logistic regression for SOD2 c.47C>T (rs4880), CC genotype significantly increased the risks of HTG [adjusted OR = 3.23 (95% CI [1.20–8.75]), p = 0.021 (Fig. S1)], high TG/HDL-C ratio (≥3.7) [adjusted OR = 2.57 (95% CI [1.06–6.24]), p = 0.037 (Fig. S2)] and HTG combined with low HDL-C (<1 mmol/L) [adjusted OR = 3.60 (95% CI [1.06–12.19]), p = 0.040 (Fig. 1)], as compared with TT. With linear regression analysis, significant associations of TC and CC genotypes with TG (log-transformed) levels were also revealed as compared with TT genotype, adjusted for age, gender, HDL-C level, smoking status, and administration of fibrate (β = 0.046 p = 0.035 and β = 0.098 p = 0.023). Moreover, CC genotype was significantly associated with TG/HDL-C ratio (log-transformed), adjusted for age, gender, smoking status, and administration of fibrate, β = 0.169, p = 0.009.

For SOD3 c.172G>A (rs2536512), comparing with GG genotype, AA genotype had higher levels of TG and TG/HDL-C ratio (Table 2) and significantly associated with HTG [adjusted OR = 2.09 (95% CI [1.08–4.05]), p = 0.029 (Fig. S1)]. Moreover, AA carriers were also associated with risk of having HTG combined with low HDL-C (<1 mmol/L) as compared with GG [adjusted OR = 2.87 (95% CI [1.27–6.50]), p = 0.011 (Fig. 1)]. After adjusting for confounding factors, a significant association of AA carriers with TG/HDL-C ratio (log-transformed) levels was also presented as compared with GG carriers (β = 0.111, p = 0.015).

SOD3 g.9892T>C (rs2855262), compared with TT, CC carriers had lower HDL-C level and higher TG/HDL-C ratio (Table 2) and were associated with risk of having HTG combined with low HDL-C [adjusted OR = 2.92 (95% CI [1.33–6.41]), p = 0.007 (Fig. 1)]. Furthermore, CC genotype was also significantly associated with TG/HDL-C ratio (log-transformed) after adjusting for confounding factors, β = 0.096, p = 0.023.

Both GPX3 c.87+1494A>G (rs3828599) and GSTT1 deletion polymorphisms revealed no genotype relationship with abnormal lipid level (Table 2). When assessed by regression analysis, however, individuals with GPX3 rs3828599 AA genotype, as comparing with GG carriers, increased risks of high TG/HDL-C ratio [adjusted OR = 2.48 (95% CI [1.34–4.59]), p = 0.004 (Fig. S2)], having low HDL-C level [<1 mmol/L; adjusted OR = 2.22 (95% CI [1.17–4.20]), p = 0.014 (Fig. S3)], and HTG combined with low HDL-C [adjusted OR = 3.31 (95% CI [1.51–7.28]), p = 0.003 (Fig. 1)]. There were no associations of GSTT1 deletion polymorphisms with either HTG alone or HTG combined with low HDL-C level; however, GSTT1–/– carriers revealed marginal association with low HDL-C level as compared with GSTT1+/+ genotype [adjusted OR = 1.70 (95% CI [0.92–3.15]),
Table 2  The relationship between genotypes/GRS groups and TG and HDL-C levels for each individual polymorphism and for a combined risk-alleles (GRS).

| Polymorphisms | TG (mmol/L) | HDL-C (mmol/L) | TG/HDL-C (unit: mmol/L) | TG/HDL-C (unit: mg/dL) |
|---------------|-------------|----------------|-------------------------|------------------------|
| TT (n = 223)  | 1.83 ± 0.93 | 1.06 ± 0.33    | 1.99 ± 1.40             | 4.57 ± 3.20            |
| TC (n = 148)  | 2.07 ± 1.39 | 1.11 ± 0.34    | 2.16 ± 2.02             | 4.95 ± 4.63            |
| SOD2 rs4880   |             |                |                         |                        |
| CC (n = 25)   | 2.45 ± 1.56 | 0.99 ± 0.25    | 2.82 ± 2.24             | 6.46 ± 5.12            |
| p-value       | 0.049       | 0.137          | 0.102                   | 0.102                  |
| p for trend   | 0.020       | 0.330          | 0.033                   | 0.033                  |
| GG (n = 146)  | 1.82 ± 1.10 | 1.10 ± 0.33    | 1.88 ± 1.52             | 4.30 ± 3.47            |
| GA (n = 190)  | 1.98 ± 1.24 | 1.09 ± 0.34    | 2.15 ± 1.87             | 4.92 ± 4.28            |
| SOD3 rs2536512|             |                |                         |                        |
| AA (n = 60)   | 2.22 ± 1.09 | 0.99 ± 0.28    | 2.54 ± 1.63             | 5.82 ± 3.74            |
| p-value       | 0.037       | 0.052          | 0.04                    | 0.04                   |
| p for trend   | 0.010       | 0.016          | 0.004                   | 0.004                  |
| TT (n = 136)  | 1.92 ± 1.36 | 1.12 ± 0.36    | 2.04 ± 2.05             | 4.66 ± 4.69            |
| TC (n = 182)  | 1.93 ± 1.10 | 1.08 ± 0.32    | 2.04 ± 1.50             | 4.67 ± 3.44            |
| SOD3 rs2855262|             |                |                         |                        |
| CC (n = 78)   | 2.08 ± 0.98 | 0.99 ± 0.28    | 2.39 ± 1.56             | 5.48 ± 3.57            |
| p-value       | 0.133       | 0.020          | 0.029                   | 0.029                  |
| p for trend   | 0.047       | 0.006          | 0.009                   | 0.009                  |
| GG (n = 127)  | 1.96 ± 1.22 | 1.13 ± 0.36    | 2.09 ± 1.81             | 4.79 ± 4.16            |
| GA (n = 195)  | 1.95 ± 1.23 | 1.06 ± 0.32    | 2.14 ± 1.85             | 4.89 ± 4.25            |
| GPX3 rs3828599|             |                |                         |                        |
| AA (n = 74)   | 1.97 ± 0.91 | 1.05 ± 0.29    | 2.06 ± 1.09             | 4.73 ± 2.51            |
| p-value       | 0.675       | 0.158          | 0.483                   | 0.483                  |
| p for trend   | 0.416       | 0.175          | 0.243                   | 0.243                  |
| GSTT1 gene    |             |                |                         |                        |
| +/+ (n = 79)  | 1.90 ± 1.02 | 1.11 ± 0.35    | 1.96 ± 1.31             | 4.48 ± 3.00            |
| del/− (n = 180)| 1.98 ± 1.25 | 1.09 ± 0.34    | 2.14 ± 1.85             | 4.91 ± 4.23            |
| polymorphism  |             |                |                         |                        |
| p-value       | 0.980       | 0.337          | 0.806                   | 0.806                  |
| p for trend   | 0.901       | 0.190          | 0.525                   | 0.525                  |
| −/− (n = 137) | 1.95 ± 1.16 | 1.04 ± 0.30    | 2.15 ± 1.76             | 4.92 ± 4.04            |
| 0–2 (n = 73)  | 1.72 ± 0.96 | 1.16 ± 0.36    | 1.74 ± 1.30             | 3.97 ± 2.97            |
| 3 (n = 82)    | 1.92 ± 1.22 | 1.10 ± 0.36    | 2.06 ± 1.78             | 4.73 ± 4.07            |
| Genetic risk  |             |                |                         |                        |
| GRS (n = 155) | 1.98 ± 1.24 | 1.07 ± 0.31    | 2.15 ± 1.89             | 4.93 ± 4.33            |
| 6–10 (n = 86) | 2.13 ± 1.16 | 1.00 ± 0.28    | 2.38 ± 1.63             | 5.46 ± 3.73            |
| p-value       | 0.092       | 0.041          | 0.023                   | 0.023                  |
| p for trend   | 0.011       | 0.004          | 0.002                   | 0.002                  |

Notes.
Continuous variables are presented as mean ± SD.

* By ANOVA with polynomial contrasts for linear trend.

\( p\)-value = 0.037.
\( p\)-value = 0.014.
\( p\)-value = 0.022.
\( p\)-value = 0.032.
\( p\)-value = 0.046.
\( p\)-value = 0.046.
### Figure 1: Adjusted Odds ratios (ORs) and 95% CI for the risk of HTG and low HDL-C (<1 mmol/L) as the function of antioxidant related gene polymorphisms.

The ORs were adjusted for age, gender, smoking status, and administration of fibrate. N, total number of genotype carriers in each group. * indicates statistically significant; *p* < 0.05.

**Full-size DOI: 10.7717/peerj.7407/fig-1**

$p = 0.092$ (Fig. S3). In addition, comparing between HOMA-IR ≥5.75 (tertile 3rd) and ≤3.40 (tertile 1), GSTT1$^{-/-}$ carriers were associated with high HOMA-IR as compared with GSTT1 presence (GSTT1$^{+/+}$) carriers; OR = 2.29 (95% CI [1.09–4.82]), *p* = 0.028 (adjusted for age, gender, DM, HTG, obesity, and cigarette smoking).

The “power of test” was also determined. Overall, this study has more than 80% power of determining for all alleles that carried OR of 2 or more (*p* < 0.05 as shown in Table S2).

### Effect of combined SOD2, SOD3, GPX3, and GSTT1 polymorphisms on the risk of TG and HDL-C dyslipidemia

To further investigate the combined effect of these five antioxidant gene polymorphisms, the genetic risk score (GRS) was constructed based on the sum of risk alleles in individual subjects. GRS was formulated based on the risk-contributing alleles across multiple polymorphisms that were significantly associated with HTG, low HDL-C, high TG/HDL-C...
ratio, combined HTG and low HDL-C, and insulin resistance (high HOMA-IR) in this study. Subjects were first categorized into four GRS groups, defined by the quartiles of all subjects, as having GRSs 0–2 \((N = 73)\), 3 \((N = 82)\), 4–5 \((N = 155)\), and 6–10 \((N = 86)\). The GRS 0–2 was then used as a reference for risk assessment in other higher GRS groups.

As expected, high GRS revealed a significant association with lipid abnormalities. The group of GRS 6-10 had lower HDL-C level and higher TG/HDL-C ratio (Table 2) and presented with increased risk of having low HDL-C level \((\text{adjusted OR (95\% CI)} = 2.70 (1.24–5.85), p = 0.012; 3.11 (1.55–6.23), p = 0.001; \text{and } 5.73 (2.22–14.77), p < 0.001)\). The associations of GRS with lipid abnormalities, except low HDL-C, remained statistically significant after applying Bonferroni correction \((p < 0.010)\). The associations of GRS 4–5 and GRS 6–10 with TG/HDL-C ratio (log-transformed) were also significant, as compared with GRS 0–2, after adjusting for confounding factors \((\beta = 0.091, p = 0.030 \text{ and } \beta = 0.150, p = 0.002)\).

**Associations of TG and HDL-C dyslipidemia with the severity of coronary atherosclerosis**

To evaluate if such abnormalities of TG and HDL-C levels could predict the severity of coronary atherosclerosis, association studies were conducted for atherosclerotic severity (Gensini score >32) as a function of lipid abnormalities as well as other CVD risk factors. Only high TG/HDL-C ratio \((\geq 3.7)\) was associated with severity of coronary atherosclerosis \((\text{GS} > 32)\) with adjusted OR \(= 2.26 (95\% \text{ CI } [1.17–4.34])\) (Table 3). Furthermore, by using a number of vessels with \(\geq 50\%\) stenosis as an indicator of atherosclerotic severity, high TG/HDL-C ratio \((\geq 3.7)\) was also associated with multi-vessel disease \((\geq 2)\) as compared with 0-1 vessel with stenosis, adjusted OR \(= 2.18 (95\% \text{ CI } [1.20–3.99])\).

**Genetic polymorphisms in SOD2, SOD3, GPX3, and GSTT1 and severity of coronary atherosclerosis**

Further investigation was carried out for the possibility that risk genotypes in these antioxidant genes could be also associated with the severity of atherosclerosis. There were no associations of all gene variants with the severity of coronary atherosclerosis \((\text{GS} > 32, \text{Table S3})\). However, \(\text{GSTT1}^{-/-}\) deletion polymorphism appeared to have the relationship with step-wise increasing GS in all subjects; the mean level of GS for each genotype was \(21.5 \pm 32.7\) for \(+/+\) \((N = 75)\), \(26.9 \pm 35.4\) for \(+/-\) \((N = 178)\), and \(27.1 \pm 34.5\) for \(-/-\) \((N = 136)\), \(p = 0.120, p \text{ for trend } = 0.041\). Although there were no significant associations of GRS with the severity of coronary atherosclerosis \((\text{Table S4})\), \(\text{GSTT1}^{-/-}\) carriers were associated with increased risk of multi-vessel CAD \((\geq 2\text{ vessels with } \geq 50\%\text{ stenosis})\) as compared with \(\text{GSTT1}^{+/+}\) carriers \((\text{OR } = 2.23, 95\% \text{ CI } [1.10–4.51], p = 0.026, \text{ adjusted for age, gender, DM, HT, waist/hip ratio, and cigarette smoking})\).

**DISCUSSION**

The present study explored the association of five antioxidant-related gene variants with atherogenic dyslipidemia in subjects with high-risk of CAD. From five gene variants being
Figure 2  Adjusted ORs and 95% CI for the risks of low HDL-C level, high TG/HDL-C ratio (≥3.7), and HTG combined with low HDL-C as the function of genetic risk score. The adjusted ORs indicating the function of combined five polymorphisms by using genetic risk score 0–2, 3, 4–5, and 6–10 are presented in (A) for low HDL-C level, (B) for high TG/HDL-C ratio, and (C) for HTG combined with low HDL-C. a The ORs were adjusted for age, gender, prevalence of HTG, smoking status, and administration of fibrate and b adjusted for age, gender, smoking status, and administration of fibrate. N, total number of combined genotype carriers in each group. * indicates statistically significant; p < 0.05.

Full-size DOI: 10.7717/peerj.7407/fig-2
### Table 3: The associations of CVD risk factors with the severity of coronary atherosclerosis.

| CVD risk factors                  | Gensini score ≤32; N (%) (n = 268) | Gensini score >32; N (%) (n = 121) | Crude Odds Ratio (95%CI) | p-value | Adjusted Odds Ratio (95%CI) | p-value |
|----------------------------------|------------------------------------|-----------------------------------|--------------------------|---------|-----------------------------|---------|
| Diabetes mellitus (DM)           | 79 (29.6%)                         | 46 (38.7%)                        | 1.50 (0.95, 2.36)        | 0.080   | 1.22 (0.62, 2.40)           | 0.559   |
| Hypertension (HT)                | 220 (82.1%)                        | 106 (87.6%)                       | 1.54 (0.83, 2.88)        | 0.174   | 1.12 (0.42, 3.01)           | 0.821   |
| Dyslipidemia (DL)                | 263 (98.1%)                        | 119 (98.3%)                       | 1.13 (0.22, 5.91)        | 0.884   | 0.68 (0.10, 4.58)           | 0.695   |
| Obesity (OB)                     | 115 (42.9%)                        | 50 (42.0%)                        | 0.96 (0.62, 1.49)        | 0.870   | 0.96 (0.61, 1.52)           | 0.877   |
| Hypertriglyceridemia (HTG)       | 127 (47.4%)                        | 68 (56.2%)                        | 1.42 (0.92, 2.19)        | 0.108   | 1.13 (0.60, 2.13)           | 0.700   |
| Low HDL-C level                  | 128 (47.8%)                        | 63 (52.1%)                        | 1.19 (0.77, 1.83)        | 0.432   | 1.27 (0.67, 2.41)           | 0.461   |
| High TG/HDL-C (≥3)               | 158 (59.0%)                        | 87 (71.9%)                        | 1.78 (1.12, 2.84)        | 0.015   | 1.95 (0.95, 4.00)           | 0.069   |
| High TG/HDL-C (≥3.7)             | 124 (46.3%)                        | 72 (59.5%)                        | 1.71 (1.10, 2.64)        | 0.016   | 2.26 (1.17, 4.34)           | 0.015   |
| HTG with normal HDL-C level      | 47 (17.5%)                         | 25 (20.7%)                        | 1.50 (0.80, 2.81)        | 0.206   | 0.82 (0.29, 2.33)           | 0.705   |
| Low HDL-C level with normal TG level | 48 (17.9%)                      | 20 (16.5%)                        | 1.17 (0.61, 2.26)        | 0.631   | 1.17 (0.44, 3.09)           | 0.750   |
| HTG and low HDL-C level          | 80 (29.9%)                         | 43 (35.5%)                        | 1.51 (0.88, 2.61)        | 0.134   | 1.36 (0.57, 3.25)           | 0.485   |

**Notes.**

*Adjusted for age, gender, HT, waist/hip ratio, and cigarette smoking.

*Adjusted for age, gender, DM, waist/hip ratio, and cigarette smoking.

*Adjusted for age, gender, HT, DM, waist/hip ratio, and cigarette smoking.

*Adjusted for age, gender, HT, DM, and cigarette smoking.

Tested, only polymorphisms in SOD2, SOD3 and GPX3 were significantly associated with HTG combined with low HDL-C (Fig. 1). For SOD2 c.47C>T (rs4880), CC genotype significantly increased risks of HTG (Fig. S1) and high TG/HDL-C ratio (Fig. S2), as compared with TT. SOD3 c.172G>A (rs2536512) significantly associated with HTG, whereas GPX3 c.87+1494A>G (rs3828599) revealed association with risks of having low HDL-C level (Fig. S3) and high TG/HDL-C. GSTT1-/- carriers, though did not have a significant association with such abnormal lipid levels, were associated with increased risk of high IR state (high HOMA-IR), a condition related to TG and HDL-C dyslipidemia. Further combined effect of five polymorphisms, expressed as a genetic risk score (GRS), was investigated; the high GRS pronounced significant association with low HDL-C, high TG/HDL-C ratio, and HTG combined with low HDL-C; with stronger effect (higher OR) was observed for both high TG/HDL-C ratio and HTG combined with low HDL-C, as compared with the effect of individual polymorphisms (Fig. 2) (significant association remained after Bonferroni correction), suggesting the interaction or additive effect of these polymorphisms on such atherogenic lipid abnormality. In the present study, the patients with “moderate to severe” atherosclerosis had significantly higher waist/hip ratio (WHR) as compared with control groups and denoted as abdominal obesity, defined by mean level of WHR above 0.95 for males and above 0.80 for females (Lean, Han & Morrison, 1995). The previous studies have reported significant positive relationships of WHR to the presence of CAD (Rashiti, Behluli & Bytyqi, 2017) and atherosclerotic severity (Scicali et al., 2018), indicating abdominal obesity as an independent risk factor for CAD. We also demonstrated that high TG/HDL-C ratio (≥3.7) independently associated with severity of coronary atherosclerosis, by using either GS >32 or the number of vessels with 50% stenosis as an indicator. This finding may indicate such a high TG/HDL-C ratio as
a potent predictor for the severity of coronary atherosclerosis. Although a combination of five antioxidant-related gene variants was not directly associated with severity of coronary atherosclerosis; they were, however, strongly associated with combined HTG and low HDL-C as well as high TG/HDL-C ratio (≥3.7), atherogenic dyslipidemia showing association with atherosclerotic severity. To the best of our knowledge, the present study is the first report for the combined effect of five genetic variants in these antioxidant-related genes on lipid abnormalities associated with severity of coronary atherosclerosis in subjects with high risk of CAD.

Regarding TG and HDL-C dyslipidemia, high TG/HDL-C ratio has also been reported with increased risks of atherosclerosis and arterial stiffness in patients with diabetes (Shimizu et al., 2013), and has been a strong independent predictor of CVD mortality, as well as incident T2DM (Vega et al., 2014). A combination of high TG with low HDL-C levels has also recently been reported to increase risks of both CAD and stroke, particularly in subjects with diabetes (Lee et al., 2017). High TG/HDL-C ratio has been associated with the extent of coronary disease and used as a surrogate marker for insulin resistance (IR) (Da Luz et al., 2008; Iwani et al., 2017).

The prevalence of subjects with high TG/HDL-C ratio [ratio ≥3 (Hannon et al., 2006; Iwani et al., 2017; McLaughlin et al., 2003)] was high, and almost all subjects (95.3%) had high HOMA-IR [≥1.56 for men and ≥1.64 for women (Do et al., 2010)], indicating the presence of IR state. HTG is the most common lipid abnormality in IR state; is due to increased production of TG-rich lipoprotein (VLDL), and is related to the occurrences of small dense LDL particles and low HDL-C level which play mechanistically role in atherogenesis and atherosclerotic progression (Welty, 2013). Therefore, lipid abnormalities in IR condition could pronounce the effect toward increasing severity of atherosclerosis, as seen in the present report.

There was an indirect genotype-outcome relationship regarding SOD gene variants associated with TG and HDL-C dyslipidemia. SOD2 rs4880 causes Ala (GCT) to Val (GTT) substitution in mitochondrial targeting peptide. The Ala-SOD2 can efficiently import into the mitochondrial matrix, whereas the Val variant causes the partial arrest of the precursor within the inner membrane and reduced the formation of active SOD2, resulting in lower SOD2 activity (Fujimoto et al., 2008; Sutton et al., 2003). However, in the present study, SOD2 rs4880-CC genotype (Ala-SOD2) increased the risks of having HTG and HTG combined with low HDL-C levels. Under metabolic disorder, higher SOD2 activity in subjects with rs4880-CC might cause higher mitochondrial H$_2$O$_2$ accumulation, leading to oxidative stress-related IR which affect HTG and low HDL-C level (Li et al., 2014). In accordance with animal studies, high-fat diet (HFD)-induced mitochondrial O$_2$•$^-$ overproduction in mouse adipocytes has resulted in increasing the rate of conversion into H$_2$O$_2$ by SOD2 and involved in IR-related HTG (Fisher-Wellman & Neufer, 2012; Li et al., 2014). Adipocyte-targeted Sod2 knockout mice prevent HFD-induced obesity and IR via increasing in mitochondrial biogenesis and fatty acid oxidation, leading to the clearance of circulating FFA and the improvement of IR (Han et al., 2016).

In a previous report, individuals with SOD3 rs2536512-A allele, causing Ala to Thr substitution at amino acid position 58 in SOD3, has presented with higher SOD activity
compared to those with G allele (Dong et al., 2014). In the present study, SOD3 rs2536512-AA genotype increased the risks of having HTG and HTG combined with low HDL-C levels. In accordance with our finding, a previous study has also demonstrated that SOD3 rs2536512-A allele carriers have higher IR and an increased risk of T2DM (Tamai et al., 2006). Furthermore, other studies have reported that serum SOD level and SOD activity are negatively correlated with HDL-C and positively correlated with TG levels in patients with cardiovascular risk factors (Gomez-Marcos et al., 2016; Yubero-Serrano et al., 2013). High SOD3 activity was expected to effectively neutralize excess O$_2^{-}$ level, however it could result in overproduction of H$_2$O$_2$, which could accumulate and induce hepatic IR (Iwakami et al., 2011). IR state promotes hepatic VLDL overproduction (increasing de novo lipogenesis) and VLDL secretion, and causes delayed clearance of plasma TG-rich lipoproteins (Taskinen & Boren, 2015). This results in elevated blood TG level which affects HDL level and particle size. High level of TG-rich lipoproteins induces cholesteryl ester transfer protein (CETP) activity in catalyzing the transfer of cholesteryl ester (CE) from HDL to TG-rich lipoproteins in exchange for TG. This exchange results in the small (TG-rich and CE-poor) HDL particles which are catabolized faster than large (CE-rich) HDL, resulting in lower levels of HDL-C (Welty, 2013). For SOD3 rs2855262, in our pilot study, the CC carriers in older subjects with MetS had the highest level of MDA, an oxidative marker, compared with other genotypes (Table S1). Furthermore, the SOD3 rs2855262 had strong linkage disequilibrium with SOD3 rs2536512. Consequently, the association between this SNP and HTG combined with low HDL-C level were also observed.

Regarding GPX3 rs3828599, by which AA carrier was also strongly associated with low HDL-C level and HTG combined with low HDL-C. Functionally, the AA genotype has been reported with increasing level of GPX3 expression (Wang et al., 2010). In animal study, human GPX3 transgenic mice had lower levels of TC and HDL-C compared to wild-type mice (Yang et al., 2009). These may suggest that high GPX3 activity promote such lipid abnormalities. Because GPX3 function in detoxifying H$_2$O$_2$ requires reduced glutathione (GSH), high GPX3 activity in the presence of high H$_2$O$_2$ level may lead to the reduction of GSH level. Majority of our study subjects had advanced age and a high prevalence of DM and MetS. GSH levels decline with age (Maher, 2005) and decrease in an individual with DM and MetS (Spanidis et al., 2016). Low GSH redox activity plays a major role in reducing insulin sensitivity (De Mattia et al., 1998), which could contribute to HTG and low HDL-C. In addition, GSH indirectly increases HDL-mediated cholesterol efflux from macrophages via ABCA1 and ABCG1 transporters (Rosenblat et al., 2014); and GSH-treated macrophage expresses a higher level of PPAR α and ABCA1 mRNA than in control cells (Rosenblat et al., 2014). GSH may, therefore, be the mediator influencing both TG and HDL levels.

Altogether, the association of SOD2, SOD3 and GPX3 polymorphisms with atherogenic dyslipidemia, observed in the present study, could result from the interplay of gene polymorphisms, their modified protein functions, and their involved antioxidant pathway, as well as the underlying condition of the study population. However, further investigation is required to confirm this hypothesis.
The association between \textit{GSTTI} deletion polymorphism and CAD risk has remained controversial \citep{Du2012}. In the present study, \textit{GSTTI} \textsuperscript{−/−} had a marginal association with severity of atherosclerosis and low HDL-C level; however, \textit{GSTTI} \textsuperscript{−/−} carriers were associated high HOMA-IR, a state of IR that may contribute to HTG and low HDL-C dyslipidemia in combination with other gene polymorphisms. \textit{GSTTI}, a cytosolic GST, plays an important role in detoxifying lipid peroxidation products \citep{Hurst1998}. In animal studies, those with lower GST activity had higher levels of TC, TG, phospholipids and lipid peroxidation \citep{Suzumura2000}. In human studies, \textit{GSTTI} \textsuperscript{−/−} carriers in adults had a lower level of HDL-C and a higher level of TG/HDL-C ratio \citep{Maciel2009}. However, the molecular mechanism underlying this association remains unclear.

A previous study in the Hungarian population has reported the relationship between catalase gene (\textit{CAT}) polymorphism (C-262T, rs1001179) and HDL-C levels \citep{Goth2012}; T2DM patients with TT had significantly lower HDL-C level than CC carriers. The present study, however, did not explore this SNP in the Thai population because rare minor allele frequency (4\%) has been reported in the Asian population \citep{Liu2016}.

The limitation of this study was the absence of functional studies to investigate the impact of the different genotypes on antioxidant gene expression and/or enzyme activity as well as oxidative stress markers in question because of an insufficient amount of fresh blood. This study was carried out only in Thai subjects, a study in other ethnic population may provide variable evidence causes by ethnic-specific genetic variations as well as the different environmental factors. In addition, relatively limited sample sizes could affect the statistical power on detecting associations. Thus, these findings should be considered exploratory until they can be replicated in a larger sample size.

**CONCLUSIONS**

In conclusion, we have demonstrated that four polymorphisms in antioxidant genes ($\textit{SOD2}$ rs4880, $\textit{SOD3}$ rs2536512 and rs2855262, and $\textit{GPX3}$ rs3828599) are independently associated with combined HTG and low HDL-C in subjects with high risk of CAD. We also provide evidence that high TG/HDL-C ratio predicts the severity of coronary atherosclerosis. We further demonstrated that high GRS derived from combined $\textit{SOD2}$, $\textit{SOD3}$, $\textit{GPX3}$, and $\textit{GSTTI}$ polymorphisms have a strong association with such atherogenic dyslipidemia. Our finding provides the evidence of indirect linking between antioxidant gene variants and the severity of coronary atherosclerosis.

**ACKNOWLEDGEMENTS**

We convey special acknowledgment to all participants in this study. We are also indebted to the Cardiovascular Research Group (CVRG), Khon Kaen University and to the Faculty of Associated Medical Sciences, Khon Kaen University for providing all necessary facilities.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
The funding for this study was supported by the National Research Council of Thailand (NRCT; Grant No. 555854). Nisa Decharatchakul was supported by Research Grant from Graduate School, Khon Kaen University (Grant No. 57212108), the Postgraduate Program in Biomedical Sciences, Graduate School, and Cardiovascular Research Group (CVRG), Khon Kaen University, Thailand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
National Research Council of Thailand: 555854.
Research Grant from Graduate School, Khon Kaen University: 57212108.
Postgraduate Program in Biomedical Sciences, Graduate School.
Cardiovascular Research Group (CVRG), Khon Kaen University, Thailand.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Nisa Decharatchakul conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Chatri Settasatian conceived and designed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
• Nongnuch Settasatian, Nantarat Komanasin, Upa Kukongviriyapan, Phongsak Intharaphet and Vichai Senthong conceived and designed the experiments, approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
All procedures performed in the present study involving human participants were approved by Khon Kaen University Ethics Committee for Human Research (Ethical Application Ref: HE510414).

Data Availability
The following information was supplied regarding data availability:
The raw measurements are available in the Supplemental File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.7407#supplemental-information.
REFERENCES

Ahmed HM, Miller M, Nasir K, McEvoy JW, Herrington D, Blumenthal RS, Blaha MJ. 2016. Primary low level of high-density lipoprotein cholesterol and risks of coronary heart disease, cardiovascular disease, and death: results from the multi-ethnic study of atherosclerosis. American Journal of Epidemiology 183:875–883 DOI 10.1093/aje/kwv305.

American Diabetes Association. 2013. Standards of medical care in diabetes–2013. Diabetes Care 36:S11–S66 DOI 10.2337/dc13-S011.

Arcaroli JJ, Hokanson JE, Abraham E, Geraci M, Murphy JR, Bowler RP, Dinarello CA, Silveira L, Sankoff J, Heyland D, Wischmeyer P, Crapo JD. 2009. Extracellular superoxide dismutase haplotypes are associated with acute lung injury and mortality. American Journal of Respiratory and Critical Care Medicine 179:105–112 DOI 10.1164/rccm.200710-1566O.

Boden MJ, Brandon AE, Tid-Ang JD, Preston E, Wilks D, Stuart E, Cleasby ME, Turner N, Cooney GJ, Kraegen EW. 2012. Overexpression of manganese superoxide dismutase ameliorates high-fat diet-induced insulin resistance in rat skeletal muscle. American Journal of Physiology Endocrinology and Metabolism 303:E798–E805 DOI 10.1152/ajpendo.00577.2011.

Cassar A, Holmes Jr DR, Rihal CS, Gersh BJ. 2009. Chronic coronary artery disease: diagnosis and management. Mayo Clinic Proceedings 84:1130–1146 DOI 10.4065/mcp.2009.0391.

Chen N, Liu Y, Greiner CD, Holtzman JL. 2000. Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides. Journal of Laboratory and Clinical Medicine 136:58–65 DOI 10.1067/mlc.2000.107692.

Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS. 2009. Gluthione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Molecular and Cellular Biology 29:20–30 DOI 10.1128/mcb.00544-08.

Crocco P, Montesanto A, Passarino G, Rose G. 2016. Polymorphisms falling within putative miRNA target sites in the 3′ UTR region of SIRT2 and DRD2 genes are correlated with human longevity. Journals of Gerontology Series A, Biological Sciences and Medical Sciences 71:586–592 DOI 10.1093/gerona/glv058.

Cui R, Gao M, Qu S, Liu D. 2014. Overexpression of superoxide dismutase 3 gene blocks high-fat diet-induced obesity, fatty liver and insulin resistance. Gene Therapy 21:840–848 DOI 10.1038/gt.2014.64.

Da Luz PL, Favarato D, Faria-Neto Jr JR, Lemos P, Chagas AC. 2008. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics 63:427–432 DOI 10.1590/S1807-59322008000400003.

De Mattia G, Bravi MC, Laurenti O, Cassone-Falsetta M, Armiento A, Ferri C, Balsano F. 1998. Influence of reduced glutathione infusion on glucose metabolism in patients
with non-insulin-dependent diabetes mellitus. *Metabolism: Clinical and Experimental* 47:993–997 DOI 10.1016/S0026-0495(98)90357-2.

Ding H, Heng B, He W, Shi L, Lai C, Xiao L, Ren H, Mo S, Su Z. 2016. Chronic reactive oxygen species exposure inhibits glucose uptake and causes insulin resistance in C2C12 myotubes. *Biochemical and Biophysical Research Communications* 478:798–803 DOI 10.1016/j.bbrc.2016.08.028.

Do HD, Lohsoonthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. 2010. Prevalence of insulin resistance and its relationship with cardiovascular disease risk factors among Thai adults over 35 years old. *Diabetes Research and Clinical Practice* 89:303–308 DOI 10.1016/j.diabres.2010.04.013.

Dong X, Li D, Liu H, Zhao Y. 2014. SOD3 and eNOS genotypes are associated with SOD activity and NO. *Experimental and Therapeutic Medicine* 8:328–334 DOI 10.3892/etm.2014.1720.

Du Y, Wang H, Fu X, Sun R, Liu Y. 2012. GSTT1 null genotype contributes to coronary heart disease risk: a meta-analysis. *Molecular Biology Reports* 39:8571–8579 DOI 10.1007/s11033-012-1691.

Fazakerley DJ, Minard AY, Krycer JR, Thomas KC, Stockli J, Harney DJ, Burchfield JG, Maghzel GJ, Caldwell ST, Hartley RC, Stocker R, Murphy MP, James DE. 2018. Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation. *Journal of Biological Chemistry* 293:7315–7328 DOI 10.1074/jbc.RA117.001254.

Fisher-Wellman KH, Neufer PD. 2012. Linking mitochondrial bioenergetics to insulin resistance via redox biology. *Trends in Endocrinology and Metabolism* 23:142–153 DOI 10.1016/j.tem.2011.12.008.

Fujimoto H, Taguchi J, Imai Y, Ayabe S, Hashimoto H, Kobayashi H, Ogasawara K, Aizawa T, Yamakado M, Nagai R, Ohno M. 2008. Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. *European Heart Journal* 29:1267–1274 DOI 10.1093/eurheartj/ehm500.

Giegerich R, Meyer F, Schleiermacher C. 1996. GeneFisher--software support for the detection of postulated genes. *Proceedings, International Conference on Intelligent Systems for Molecular Biology* 4:68–77.

Gomez-Marcos MA, Blazquez-Medela AM, Gamella-Pozuelo L, Recio-Rodriguez JJ, Garcia-Ortiz L, Martinez-Salgado C. 2016. Serum superoxide dismutase is associated with vascular structure and function in hypertensive and diabetic patients. *Oxidative Medicine and Cellular Longevity* 2016:Article 9124676 DOI 10.1155/2016/9124676.

Goth L, Nagy T, Kosa Z, Fejes Z, Bhattoa HP, Paragh G, Kaplan M. 2012. Effects of rs769217 and rs1001179 polymorphisms of catalase gene on blood catalase, carbohydrate and lipid biomarkers in diabetes mellitus. *Free Radical Research* 46:1249–1257 DOI 10.3109/10715762.2012.702899.

Han YH, Buffolo M, Pires KM, Pei S, Scherer PE, Boudina S. 2016. Adipocyte-specific deletion of manganese superoxide dismutase protects from diet-induced obesity
through increased mitochondrial uncoupling and biogenesis. *Diabetes* **65**:2639–2651 DOI 10.2337/db16-0283.

Hannon TS, Bacha F, Lee SJ, Janosky J, Arslanian SA. 2006. Use of markers of dyslipidemia to identify overweight youth with insulin resistance. *Pediatric Diabetes* **7**:260–266 DOI 10.1111/j.1399-5448.2006.00199.

Hao Y, Wu BG, Shi J, Chen YL, Sun ZQ, Zheng LQ, Zhang XG, Geng N, Li TJ, Li H, Sun YX. 2011. Association of tag SNPs of GPx-3 with essential hypertension in rural Han Chinese in Fuxin, Liaoning, China. *Chinese Medical Journal* **124**:2113–2116 DOI 10.3760/cma.j.issn.0366-6999.2011.14.006.

Hurst R, Bao Y, Jemth P, Mannervik B, Williamson G. 1998. Phospholipid hydroperoxide glutathione peroxidase activity of human glutathione transferases. *Biochemical Journal* **332**(Pt 1):97–100 DOI 10.1042/bj3320097.

Ioannidis JPA. 2003. Genetic associations: false or true? *Trends in Molecular Medicine* **9**:135–138 DOI 10.1016/S1471-4914(03)00030-3.

Iwakami S, Misu H, Takeda T, Sugimori M, Matsugo S, Kaneko S, Takamura T. 2011. Concentration-dependent dual effects of hydrogen peroxide on insulin signal transduction in H4IIEC hepatocytes. *PLOS ONE* **6**:e27401 DOI 10.1371/journal.pone.0027401.

Iwani NA, Jalaludin MY, Zin RM, Fuziah MZ, Hong JY, Abqariyah Y, Mokhtar AH, Wan Nazaimoon WM. 2017. Triglyceride to HDL-C Ratio is associated with insulin resistance in overweight and obese children. *Scientific Reports* **7**:40055 DOI 10.1038/srep40055.

Karlsson K, Lindahl U, Marklund SL. 1988. Binding of human extracellular superoxide dismutase C to sulphated glycosaminoglycans. *Biochemical Journal* **256**:29–33 DOI 10.1042/bj2560029.

Karnati S, Luers G, Pfreimer S, Baumgart-Vogt E. 2013. Mammalian SOD2 is exclusively located in mitochondria and not present in peroxisomes. *Histochemistry and Cell Biology* **140**:105–117 DOI 10.1007/s00418-013-1099-4.

Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. 2017. Oxidative stress in atherosclerosis. *Current Atherosclerosis Reports* **19**:Article 42 DOI 10.1007/s11883-017-0678-6.

Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A. 2016. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. *Circulation: Cardiovascular Quality and Outcomes* **9**:100–108 DOI 10.1161/circoutcomes.115.002104.

Lean ME, Han TS, Morrison CE. 1995. Waist circumference as a measure for indicating need for weight management. *British Medical Journal* **311**:158–161 DOI 10.1136/bmj.311.6998.158.

Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. 2017. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study. *Diabetes Care* **40**:529–537 DOI 10.2337/dc16-1958.
Li N, Fu J, Koonen DP, Kuivenhoven JA, Snieder H, Hofker MH. 2014. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? *Atherosclerosis* 233:130–138 DOI 10.1016/j.atherosclerosis.2013.12.013.

Liu KL, Kuo WC, Lin CY, Lii CK, Liu YL, Cheng YH, Tsai CW. 2018. Prevention of 4-hydroxynonenal-induced lipolytic activation by carnosic acid is related to the induction of glutathione S-transferase in 3T3-L1 adipocytes. *Free Radical Biology and Medicine* 121:1–8 DOI 10.1016/j.freeradbiomed.2018.04.567.

Liu K, Liu X, Wang M, Wang X, Kang H, Lin S, Yang P, Dai C, Xu P, Li S, Dai Z. 2016. Two common functional catalase gene polymorphisms (rs1001179 and rs794316) and cancer susceptibility: evidence from 14,942 cancer cases and 43,285 controls. *Oncotarget* 7:62954–62965 DOI 10.18632/oncotarget.10617.

Maciel SS, Pereira Ada C, Silva GJ, Rodrigues MV, Mill JG, Krieger JE. 2009. Association between glutathione S-transferase polymorphisms and triglycerides and HDL-cholesterol. *Atherosclerosis* 206:204–208 DOI 10.1016/j.atherosclerosis.2009.02.011.

Maher P. 2005. The effects of stress and aging on glutathione metabolism. *Ageing Research Reviews* 4:288–314 DOI 10.1016/j.arr.2005.02.005.

Maslov LN, Naryzhnaya NV, Boshchenko AA, Popov SV, Ivanov VV, Oeltgen PR. 2019. Is oxidative stress of adipocytes a cause or a consequence of the metabolic syndrome? *Journal of Clinical & Translational Endocrinology* 15:1–5 DOI 10.1016/j.jcte.2018.11.001.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419 DOI 10.1007/BF00280883.

McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. 2003. Use of metabolic markers to identify overweight individuals who are insulin resistant. *Annals of Internal Medicine* 139:802–809 DOI 10.7326/0003-4819-139-10-200311180-00007.

Meigs JB, Larson MG, Fox CS, Keaney Jr JF, Vasan RS, Benjamin EJ. 2007. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham offspring study. *Diabetes Care* 30:2529–2535 DOI 10.2337/dc07-0817.

Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST, Vaccarino V, Zafari AM, Samady H, Quyyumi AA. 2012. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. *American Heart Journal* 164:547–552 DOI 10.1016/j.ahj.2012.07.007.

Park K, Gross M, Lee DH, Holvoet P, Himes JH, Shikany JM, Jacobs Jr DR. 2009. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. *Diabetes Care* 32:1302–1307 DOI 10.2337/dc09-0259.

Petrovic D, Peterlin B. 2014. GSTM1-null and GSTT1-null genotypes are associated with essential arterial hypertension in patients with type 2 diabetes. *Clinical Biochemistry* 47:574–577 DOI 10.1016/j.clinbiochem.2014.03.012.

Pinheiro DS, Rocha Filho CR, Mundim CA, Junior Pde M, Ulhoa CJ, Reis AA, Ghedini PC. 2013. Evaluation of glutathione S-transferase GSTM1 and GSTT1
deletion polymorphisms on type-2 diabetes mellitus risk. *PLOS ONE* 8:e76262 DOI 10.1371/journal.pone.0076262.

Rashiti P, Behluli I, Bytyqi AR. 2017. Assessment of the correlation between severity of coronary artery disease and waist-hip ratio. *Open Access Macedonian Journal of Medical Sciences* 5:929–933 DOI 10.3889/oamjms.2017.211.

Reis A, Spickett CM. 2012. Chemistry of phospholipid oxidation. *Biochimica et Biophysica Acta* 1818:2374–2387 DOI 10.1016/j.bbamem.2012.02.002.

Rosenblat M, Volkova N, Khatib S, Mahmood S, Vaya J, Aviram M. 2014. Reduced glutathione increases quercetin stimulatory effects on HDL- or apoA1-mediated cholesterol efflux from J774A.1 macrophages. *Free Radical Research* 48:1462–1472 DOI 10.3109/10715762.2014.963574.

Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL, Gibbons RJ, Cheitlin MD, Gardner TJ, Garson Jr A, Ryan TJ, Smith Jr SC. 1999. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. *Journal of the American College of Cardiology* 33:1756–1824 DOI 10.1016/S0735-1097(99)00126-6.

Scicali R, Rosenbaum D, Di Pino A, Giral P, Cluzel P, Redheuil A, Piro S, Rabuazzo AM, Purrello F, Bruckert E, Gallo A. 2018. An increased waist-to-hip ratio is a key determinant of atherosclerotic burden in overweight subjects. *Acta Diabetologica* 55:741–749 DOI 10.1007/s00592-018-1144-9.

Shavva VS, Bogomolova AM, Nikitin AA, Dizhe EB, Oleinikova GN, Lapikov IA, Tanyanskii DA, Perevozchikov AP, Orlov SV. 2017. FOXO1 and LXRalpha downregulate the apolipoprotein A-I gene expression during hydrogen peroxide-induced oxidative stress in HepG2 cells. *Cell Stress and Chaperones* 22:123–134 DOI 10.1007/s12192-016-0749-6.

Shimizu Y, Nakazato M, Sekita T, Kadota K, Yamasaki H, Takamura N, Aoyagi K, Maeda T. 2013. Association of arterial stiffness and diabetes with triglycerides-to-HDL cholesterol ratio for Japanese men: the Nagasaki Islands Study. *Atherosclerosis* 228:491–495 DOI 10.1016/j.atherosclerosis.2013.03.021.

Song Y, Shan Z, Luo C, Kang C, Yang Y, He P, Li S, Chen L, Jiang X, Liu L. 2017. Glutathione S-Transferase T1 (GSTT1) null polymorphism, smoking, and their interaction in coronary heart disease: a comprehensive meta-analysis. *Heart, Lung and Circulation* 26:362–370 DOI 10.1016/j.hlc.2016.07.005.

Souiden Y, Mallouli H, Meskhi S, Chaabouni Y, Rebai A, Cheour F, Mahdouani K. 2016. MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity. *Biological Research* 49:Article 22 DOI 10.1186/s40659-016-0083-6.

Spanidis Y, Mpesios A, Stagos D, Goutzourelas N, Bar-Or D, Karapetsa M, Zakythinos E, Spandidos DA, Tsatsakis AM, Leon G, Kouretas D. 2016. Assessment of the redox status in patients with metabolic syndrome and type 2 diabetes...
reveals great variations. *Experimental and Therapeutic Medicine* **11**:895–903 DOI 10.3892/etm.2016.2968.

Sprenger R, Schlagenhaufer R, Kerb R, Bruhn C, Brockmoller J, Roots I, Brinkmann U. 2000. Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a tri-modular genotype-phenotype correlation. *Pharmacogenetics* **10**:557–565 DOI 10.1097/00008571-200008000-00009.

Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. 2003. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. *Pharmacogenetics* **13**:145–157 DOI 10.1097/01.fpc.000004067.64000.8.

Suzumura K, Kasahara E, Ohnishi Y, Chien KC, Inoue M. 2000. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits. *Clinical and Experimental Pharmacology and Physiology* **27**:709–714 DOI 10.1046/j.1440-1681.2000.03315.

Tamai M, Furuta H, Kawashima H, Doi A, Hamanishi T, Shimomura H, Sakagashira S, Nishi M, Sasaki H, Sanke T, Nanjo K. 2006. Extracellular superoxide dismutase gene polymorphism is associated with insulin resistance and the susceptibility to type 2 diabetes. *Diabetes Research and Clinical Practice* **71**:140–145 DOI 10.1016/j.diabres.2005.05.006.

Taskinen MR, Boren J. 2015. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. *Atherosclerosis* **239**:483–495 DOI 10.1016/j.atherosclerosis.2015.01.039.

Vats P, Sagar N, Singh TP, Banerjee M. 2015. Association of Superoxide dismutases (SOD1 and SOD2) and Glutathione peroxidase 1 (GPx1) gene polymorphisms with type 2 diabetes mellitus. *Free Radical Research* **49**:17–24 DOI 10.3109/10715762.2014.971782.

Vega GL, Barlow CE, Grundy SM, Leonard D, DeFina LF. 2014. Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. *Journal of investigative medicine: the official publication of the American Federation for Clinical Research* **62**:345–349 DOI 10.2310/jim.0000000000000044.

Wang JY, Yang IP, Wu DC, Huang SW, Wu JY, Juo SH. 2010. Functional glutathione peroxidase 3 polymorphisms associated with increased risk of Taiwanese patients with gastric cancer. *Clinica Chimica Acta* **411**:1432–1436 DOI 10.1016/j.cca.2010.05.026.

Weber MA, Schiffin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Matson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. 2014. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *Journal of Clinical Hypertension* **16**:14–26 DOI 10.1111/j.ch.12237.
Welty FK. 2013. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? *Current Cardiology Reports* 15:Article 400 DOI 10.1007/s11886-013-0400-4.

World Health Organization (WHO). 2000. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. Available at https://apps.who.int/iris/handle/10665/206936.

Yang X, Deignan JL, Qi H, Zhu J, Qian S, Zhong J, Torosyan G, Majid S, Falkard B, Kleinhanz RR, Karlsson J, Castellani LW, Mumick S, Wang K, Xie T, Coon M, Zhang C, Estrada-Smith D, Farber CR, Wang SS, Van Nas A, Ghazalpour A, Zhang B, Macneil DJ, Lamb JR, Dipple KM, Reitman ML, Mehrabian M, Lum PY, Schadt EE, Lusis AJ, Drake TA. 2009. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. *Nature Genetics* 41:415–423 DOI 10.1038/ng.325.

Yang YM, Xie XR, Jin AL. 2016. Genetic polymorphisms in extracellular superoxide dismutase Leu53Leu, Arg213Gly, and Ala40Thr and susceptibility to type 2 diabetes mellitus. *Genetics and Molecular Research* 15:Article gmr15048418 DOI 10.4238/gmr15048418.

Yongsakulchai P, Settasatian C, Settasatian N, Komanasin N, Kukongwiriyapan U, Cote ML, Intharapetch P, Senthong V. 2016. Association of combined genetic variations in PPARgamma, PGC-1alpha, and LXRalpha with coronary artery disease and severity in Thai population. *Atherosclerosis* 248:140–148 DOI 10.1016/j.atherosclerosis.2016.03.005.

Yubero-Serrano EM, Delgado-Lista J, Pena-Orihuela P, Perez-Martinez P, Fuentes F, Marin C, Tinez I, Tinahones FJ, Perez-Jimenez F, Roche HM, Lopez-Miranda J. 2013. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. *Experimental and Molecular Medicine* 45:e28 DOI 10.1038/emm.2013.53.